• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Johnson & Johnson

Johnson & Johnson

Johnson & Johnson JNJ 3 Star

Last Price$95.17Day Change (%)-1.09%
Open Price$95.93Day Change ($)-1.05
Day Range94.38–96.2952-Week Range81.79–109.49

As of Fri 8/28/2015 7:50:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. How Harry Styles may have hurt SeaWorld

    How Harry Styles may have hurt SeaWorld

  2. Research and Markets: Market Analysis of Global Pharmaceutical Industries and Trend Estimation Featuring Pfizer, Johnson and Johnson , Abbott, Gilead, Sun Pharma, Glaxo Smith Kline & Eli Lilly & ...

    Research and Markets: Market Analysis of Global Pharmaceutical Industries and Trend Estimation Featuring Pfizer, Johnson and Johnson , Abbott, Gilead, Sun Pharma, Glaxo Smith Kline & Eli Lilly & Company

  3. UPDATE: America, like Coke, sweetens on Stevia

    UPDATE: America, like Coke, sweetens on Stevia

  4. UPDATE: America, like Coke, sweetens on Stevia

    UPDATE: America, like Coke, sweetens on Stevia

  5. Lilly, AACE Mark 10th Anniversary of Hurricane Katrina with Reminder of "My Diabetes Emergency Plan" Checklist

    Lilly, AACE Mark 10th Anniversary of Hurricane Katrina with Reminder of "My Diabetes Emergency Plan" Checklist

  6. U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent

    U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent

  7. Caution: Slowing Growth Ahead for J &J

    Strong drug sales helped wide-moat J & J report a steady quarter, but increasing competitive threats to leading drugs and a relatively weak late-stage pipeline will be headwinds in the future.

  8. Active vs. Passive Investing: A Bottom Line

    Chattem's CHTT second-quarter results were in line with our expectations, so our fair value estimate for the shares remains unchanged. The firm is already reaping the benefits of the five brands it acquired from Johnson & Johnson JNJ in early January in the form of sales growth and improving ...

  9. Fitch: Even as FDA Approvals Slow, Cancer Treatments Progress in Pharma R&D Pipeline

    Fitch: Even as FDA Approvals Slow, Cancer Treatments Progress in Pharma R&D Pipeline

  10. Recommended Public Cash Offer by FedEx for All Issued and Outstanding Ordinary Shares of TNT Express

    Recommended Public Cash Offer by FedEx for All Issued and Outstanding Ordinary Shares of TNT Express

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.